Impact of social cognitive deficits on community functioning

Bechi, Margherita; Spangaro, Marco

doi:10.1016/b978-0-12-815315-4.00004-5

Cited by 5 publications

(6 citation statements)

References 177 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Social cognition is composed by multiple potential domains and multiple tasks can thus be used to measure it. While it is widely acknowledged that social cognition is a major determinant of functioning in schizophrenia with both direct and indirect effect, mediating neurocognition, it is less clear which domain of social cognition most strongly affect outcomes ( Bechi and Spangaro, 2019 ). The Social Cognition Psychometric Evaluation (SCOPE) study ( Pinkham et al, 2014 ) was conducted to identify and improve existing measures of social cognition so they can be suitably applied in large-scale treatment studies.…”

Section: Cognitive Assessment: “Are We Measuring the Right Stuff”?mentioning

confidence: 99%

Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art

Harvey

Bosia

Cavallaro

et al. 2022

Schizophrenia Research: Cognition

View full text Add to dashboard Cite

Section: Cognitive Assessment: “Are We Measuring the Right Stuff”?mentioning

confidence: 99%

Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art

Harvey

Bosia

Cavallaro

et al. 2022

Schizophrenia Research: Cognition

View full text Add to dashboard Cite

“…It has been suggested that future diagnostic standards for schizophrenia should take cognitive impairment into account. 16,17 This may support the idea that patients with schizophrenia should receive routine cognitive testing, such as the Brief Assessment of Cognition in Schizophrenia (BACS). 18…”

Section: Introductionmentioning

confidence: 85%

Cognitive Outcomes in Nonacute Patients With Schizophrenia Treated With Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics

Petric,

Teodorescu,

Miron

et al. 2024

American Journal of Therapeutics

View full text Add to dashboard Cite

Background: Patients with schizophrenia often face challenges related to cognitive function, affecting their daily functioning and overall quality of life. The choice of antipsychotic treatment may play a crucial role in determining cognitive outcomes. Study Question: Our study aimed to investigate whether there was a difference in cognitive ability between the patients with schizophrenia receiving oral antipsychotics (OAP) versus long-acting injectable antipsychotics (LAI-APs). Study Design: We conducted a cross-sectional study using analytical methods between January 1, 2020, and January 1, 2022. Participants were divided into 2 groups: patients undergoing treatment with OAP and patients undergoing treatment with LAI-AP. All participants underwent version A of Brief Assessment of Cognition in Schizophrenia (BACS). Measures and Outcomes: The primary objective was to compare cognitive function in patients with schizophrenia treated with LAI antipsychotics versus OAP using BACS. Primary outcome measures include overall BACS score, with secondary measures focusing on specific cognitive domains. This study contributes to the understanding of the cognitive effects of different antipsychotic formulations in schizophrenia treatment. Results: Although there was a slightly higher intelligence quotient in the LAI-AP group (102.2 vs. 101.32, P = 0.5401), it was not statistically significant. Olanzapine was the most commonly prescribed antipsychotic, with 48% of patients in the LAI-AP group and 40% in the OAP group. The LAI-AP group outperformed in all BACS evaluations. The most notable difference was in the token motor task (57.78 ± 17.03 vs. 50.04 ± 18.82, P = 0.0335), while the Tower of London test showed the smallest difference (17.26 ± 2.61 vs. 15.48 ± 3.47, P = 0.0046). Regression analysis revealed no significant variance in intelligence quotient scores; however, a significant discrepancy in BACS scores was evident, favoring the LAI treatment for better cognitive outcomes. Conclusions: The use of long-acting antipsychotic treatment in individuals with schizophrenia offers promising advantages in preserving cognitive function.

show abstract

“…Across studies, SC is considered one of the most important determinants of recovery in SZ, with both direct and indirect effect, mediating neurocognition; however, it is unclear which SC domain most strongly affects recovery [69].…”

Section: Discussionmentioning

confidence: 99%

“…This finding is consistent with prior findings indicating that one in seven patients with SZ achieve a recovery phase that reflects both normalized social and vocational functioning and symptoms remission and lasts ≥2 years. Across studies, SC is considered one of the most important determinants of recovery in SZ, with both direct and indirect effects, mediating NC; however, it is unclear which SC domain most strongly affects recovery [ 69 ].…”

Section: Discussionmentioning

confidence: 99%

Does social cognition change? Evidence after 4 years from the Italian Network for Research on Psychoses

et al. 2023

View full text Add to dashboard Cite

show abstract

Impact of social cognitive deficits on community functioning

Cited by 5 publications

References 177 publications

Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art

Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art

Cognitive Outcomes in Nonacute Patients With Schizophrenia Treated With Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics

Does social cognition change? Evidence after 4 years from the Italian Network for Research on Psychoses

Contact Info

Product

Resources

About